Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310867 · ClinicalTrials.gov registry record · Phase 2
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
A Phase 2 study of Immunosuppression, sponsored by Linda Cendales.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02310867 is a Phase 2 study of Immunosuppression that is actively recruiting participants, run by Linda Cendales. The registered enrollment target is 50 participants, below the 643-participant average among 12 other Immunosuppression trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02310867, a Phase 2 study of Immunosuppression, is actively recruiting participants, sponsored by Linda Cendales.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test. Study activities include several study visits over 18 months and include; demographics, medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have loss of limb will be included in study evaluation. Risks of the study include risk of rejection and infection after being transplanted. Additional risk are associated with procedures that include blood draws, biopsies, x-rays, and potential loss of confidentiality. All patient data will be kept electronically and in accordance with the requirements of Duke University. In addition to the experimental data, this database includes recipient and donor demographics and transplant relevant medical history, range of motion, sensation, and immunosuppressive medications. Data will be recorded and reported in accordance with the standards required by the United Network for Organ Sharing (UNOS).
Conditions Studied
Interventions
- DRUG Belatacept
- PROCEDURE Hand transplant
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-03 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02310867
The ClinicalTrials.gov registry entry for NCT02310867 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 643-participant average among 12 other Immunosuppression trials with a reported enrollment target (92% lower). The listed sponsor is Linda Cendales, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immunosuppression appearing as the primary indexed condition, and to 2 interventions - of which Belatacept is the first listed.
NCT02310867 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02310867 about?
NCT02310867 is a clinical study titled "Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy". The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily ...
What is the current status of trial NCT02310867?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2015-03. Estimated completion is 2028-06.
What conditions does trial NCT02310867 study?
This clinical trial studies the following conditions: Immunosuppression.
What interventions are being tested in trial NCT02310867?
The interventions under investigation include: Belatacept (DRUG), Hand transplant (PROCEDURE).
Who is sponsoring clinical trial NCT02310867?
This trial is sponsored by Linda Cendales, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02310867 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunosuppression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
COMPLETED · Phase 2
-
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
COMPLETED · Phase 2
-
Pathological Myeloid Activation After Sepsis and Trauma
RECRUITING
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Vascularized Composite Bladder Allograft Transplantation
RECRUITING · NA
-
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.